Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study

Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti

Article Type

Original Research

Published

The aim of this prospective study is to evaluate the efficacy and activity of the different oncological treatments in patients with HR+/HER– metastatic breast cancer progressing to CDK4/6i therapy in a real-world setting.

Read more

Palbociclib in metastatic breast cancer: current evidence and real-life data

Francesco Serra MD, Pietro Lapidari MD, Erica Quaquarini MD, Barbara Tagliaferri MD, Federico Sottotetti MD, Raffaella Palumbo MD, PhD

Article Type

Review

Published

This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.